Skip To Main Content
P.S. Hall on Muck Rack

P.S. Hall

As seen in: Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to P.S. Hall’s profile

Articles by P.S. Hall

An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer

|
By M. T. Fallon, M. J. Leng, P.S. Hall, K. Dierberger
| annalsofoncology.org
Procedures In the control arm, patients received a weak opioid, either tramadol (maximum dose 100 mg qds) or codeine (maximum dose 60 mg qds), the choice of which, along with the starting dose, was made by the local investigator. Breakthrough analgesics (either weak or strong opioids) were not permitted in the control arm as patients were already on a maximum recommended dose of a weak opioid. The maximum doses and exclusion of breakthrough use were in line with WHO guidance.
Open in Who Shared Issue with article?

Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment Trial Findings at a National Level

|
By C.R. Hanna, E. W. Lemmon, P.S. Hall, H. T. Ennis, E. Morris, P. McLoone, R.J. Jones, K.A. Boyd
| Clinical Oncology Verified
Highlights • Anonymised chemotherapy prescribing data analysed at a national level. • Interrupted time series analysis used to investigate clinical practice change. • An example of research impact assessment applied to a cancer trial. Abstract Aims The Short Course Oncology Treatment (SCOT) trial indicated that 3 months of adjuvant doublet chemotherapy was non-inferior to 6 months of treatment for patients with colorectal cancer, with considerably less toxicity.
Open in Who Shared Issue with article?

Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy

|
By E. Tzolos, P.D. Adamson, P.S. Hall
| Clinical Oncology Verified
Introduction Anthracyclines are associated with cardiotoxicity and the development of heart failure [1x[1]Henriksen, P.A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018; 104: 971–977 Google ScholarSee all References1].
Open in Who Shared Issue with article?
Show More